Autosomal Dominant Polycystic Kidney Disease Pipeline Offers Novel Treatment Options | 12+ Companies & 12+ Drugs

 Breaking News
  • No posts were found

Autosomal Dominant Polycystic Kidney Disease Pipeline Offers Novel Treatment Options | 12+ Companies & 12+ Drugs

December 05
16:44 2022
Autosomal Dominant Polycystic Kidney Disease Pipeline Offers Novel Treatment Options | 12+ Companies & 12+ Drugs

DelveInsight’s, “Autosomal dominant polycystic kidney disease Pipeline Insight, 2022,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Autosomal dominant polycystic kidney disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Autosomal dominant polycystic kidney disease Pipeline Report

  • DelveInsight’s Autosomal dominant polycystic kidney disease pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Autosomal dominant polycystic kidney disease treatment.
  • The leading Autosomal dominant polycystic kidney disease Companies are working such as Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others.
  • Promising Autosomal dominant polycystic kidney disease Pipeline therapies such as Tolvaptan, GLPG2737, Lixivaptan, Everolimus, Tolvaptan (OPC-41061), and others.
  • In the coming years, the Autosomal dominant polycystic kidney disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Autosomal dominant polycystic kidney disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Recent Developmental Activities in the Autosomal dominant polycystic kidney disease Pipeline

  • In December 2020, we announced the first dosing with GLPG2737 in the Phase 2 MANGROVE trial in patients with ADPKD and in November 2021 full patient recruitment with topline results anticipated in the first half of 2023. GLPG2737 is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) inhibitor which was observed to be well tolerated by patients in previous clinical trials. It is hypothesized that inhibition of the CFTR channel might reduce cyst growth and enlargement for patients with autosomal dominant polycystic kidney disease (ADPKD).
  • Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA and European Commission have granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (“ADPKD”). Bardoxolone is currently being studied in FALCON, a Phase 3 study for the treatment of CKD caused by ADPKD, EAGLE, an open-label, extended access trial in patients with CKD caused by Alport syndrome who participated in the CARDINAL trial and patients with ADPKD who participated in the FALCON trial, and AYAME, a Phase 3 study for the treatment of diabetic kidney disease that is being conducted by Kyowa Kirin in Japan.

 

Request a sample and discover the recent advances in Autosomal dominant polycystic kidney disease Treatment drugs @ Autosomal dominant polycystic kidney disease Pipeline Outlook Report

 

Autosomal dominant polycystic kidney disease Overview

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the formation of cysts within the kidneys. Symptoms caused by cyst formation in the kidneys include high blood pressure (hypertension), pain on the sides of the body between the last rib and the hip (flank pain), blood in the urine (hematuria) and progressively poor function of the kidneys (kidney insufficiency).   In most patients, ADPKD eventually progresses to cause end stage renal disease, requiring renal replacement therapy, either dialysis or renal transplantation. ADPKD is not simply a kidney disorder and other organ systems of the body can potentially be affected (multisystem disorder) by the development of cysts. The specific symptoms present in each person depend upon the specific organ systems involved.

The liver, pancreas, a membrane covering the spinal cord and brain (arachnoid membrane), the prostate, and the glands of the male reproductive tract that produce fluid that is part of semen (seminal vesicles) may become involved. Abnormalities affecting the heart and blood vessels (cardiovascular system) may also occur in individuals with ADPKD. ADPKD usually does not become apparent until the fourth or fifth decade and was once known as “adult” polycystic kidney disease. However, it has been reported in children and infants. ADPKD is caused by mutations of one of two genes that create certain proteins essential for the proper health of the kidneys and other parts of the body. Approximately 85 % have ADPKD1, the most aggressive form of the disease; those with ADPKD2 progress to kidney insufficiency about 20 years later.

 

Autosomal dominant polycystic kidney disease Pipeline Insight Report

In the Autosomal dominant polycystic kidney disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Autosomal dominant polycystic kidney disease clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autosomal dominant polycystic kidney disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Autosomal dominant polycystic kidney disease Emerging Drugs Profile

  • GLPG2737: Galapagos NV
  • Bardoxolone methyl: Reata Pharmaceuticals

 

Find out more about Autosomal dominant polycystic kidney disease drugs @ Autosomal dominant polycystic kidney disease Treatment Landscape

 

Autosomal dominant polycystic kidney disease Pipeline Therapeutics Assessment

The Autosomal dominant polycystic kidney disease pipeline report proffers an integral view of the Autosomal dominant polycystic kidney disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Autosomal dominant polycystic kidney disease Pipeline Report

  • Coverage- Global
  • Autosomal dominant polycystic kidney disease Companies- Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others.
  • Autosomal dominant polycystic kidney disease Pipeline therapies- Tolvaptan, GLPG2737, Lixivaptan, Everolimus, Tolvaptan (OPC-41061), and others
  • Autosomal dominant polycystic kidney disease Unmet Needs, Market Drivers and Barriers

 

Dive deep into rich insights for drugs for Autosomal dominant polycystic kidney disease treatment, visit @ Autosomal dominant polycystic kidney disease Clinical Trials Analysis

 

Table of Content

  1. Introduction
  2. Autosomal dominant polycystic kidney disease Executive Summary
  3. Autosomal dominant polycystic kidney disease: Overview
  4. Autosomal dominant polycystic kidney disease Pipeline Therapeutics
  5. Autosomal dominant polycystic kidney disease Therapeutic Assessment
  6. Autosomal dominant polycystic kidney disease – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Bardoxolone methyl: Reata Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GLPG2737: Galapagos NV
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AL 01211: AceLink Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. AT 20494: Anakuria Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Autosomal dominant polycystic kidney disease Key Companies
  21. Autosomal dominant polycystic kidney disease Key Products
  22. Autosomal dominant polycystic kidney disease- Unmet Needs
  23. Autosomal dominant polycystic kidney disease- Market Drivers and Barriers
  24. Autosomal dominant polycystic kidney disease- Future Perspectives and Conclusion
  25. Autosomal dominant polycystic kidney disease Analyst Views
  26. Autosomal dominant polycystic kidney disease Key Companies
  27. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Autosomal dominant polycystic kidney disease drugs?
  • How many Autosomal dominant polycystic kidney disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Autosomal dominant polycystic kidney disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Autosomal dominant polycystic kidney disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Autosomal dominant polycystic kidney disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Autosomal dominant polycystic kidney disease pipeline therapeutics, reach out @ Autosomal dominant polycystic kidney disease Emerging Drugs

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles

Categories